Biobase Clinical Coagulation Analyzer Bk-Ca02 PT Aptt Tt Fib Detection

Name: Biobase Clinical Coagulation Analyzer Bk-Ca02 PT Aptt Tt Fib Detection
Brand: Biobase Biozone Co., Ltd.
SKU: 1914983372

Shandong, ChinaBiobase Biozone Co., Ltd.

US$400.00-445.00

1 Piece

Sample price:US$445.00/piece.Request sample

Product profile

Customization

Available

Classification

Imaging Diagnostic Equipment

Type

Auto Coagulation Analyzer

Model NO.

BK-CA02

Certification

Group

All

Model

Bk-Ca02

Test Principle

Optical Colorimetry

Test Items

PT, Aptt, Tt, Fib

Test Channel

Wavelength

470nm

Detection Time

Normal Sample Detection Time Is 20 to 40 Seconds,

Sample Incubation Position

Reagent Incubation Position

Detection Position Temperature

37.0±1.0°C

Incubation Position Temperature

37.0±1.0°C

Incubation Time

1~999s

Reaction Time

1~99s

Reagent Dosage

Minimum Dosage 20μL

Sample Volume

20μL~40μL

Display

7-Inch High-Definition Color Touch Screen

Transport Package

Wooden

Specification

630*610*520mm

Trademark

BIOBASE

Origin

Shandong, China

Production Capacity

100units/Month

Company profile

High Repeat Buyers ChoiceExhibition ExperienceMulti-language PioneerExperienced Team

Biobase Biozone Co., Ltd.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 8 years CertifiedNearest Port: Qingdao PortAverage Response Time: ≤3.07h

AI-Powered supplier vetting

SummaryThe supplier is identified as a combined company with eight production lines, reported annual productivity of 500,000 medical freezers, and two quality inspectors. It demonstrates broad customization and ODM capabilities, has introduced new products within the past year, and provides OEM services for well-known brands. Service procedures for supplier capability, corrective and preventive actions, and customer complaints are documented and supported by records. Overseas support includes installation, training, repair, debugging, and maintenance, with inventory and an overseas warehouse available. However, the supplier lacks overseas agents or branches, an overseas showroom, and a valid manufacturing-capacity contract with related subcontractors. Quality-control limitations include finished-product checks performed by packing staff and no continuous batch quantity reconciliation or outsourcing SOP. The supplied information does not establish certifications, financial strength, or specific customer case details.

Supplier typeThe supplier is explicitly classified as a combined company and is not an offshore company. The available information does not further define its ownership structure or operating model.

After-Sales capabilityThe supplier has documented procedures and records for handling customer complaints and corrective/preventive actions, and offers overseas installation, training, repair, debugging, and maintenance. It also reports inventory and an overseas warehouse, but has no overseas agents or branches and offers services in zero stated countries.

R&D capabilityThe supplier reports new products within the past year, provides ODM services, and supports multiple forms of design customization. ERP-based digital management is also reported, while no SDK is available; overall evidence supports product-development capability but not software-development capability.

Production capacityThe supplier reports eight production lines and annual productivity of 500,000 medical freezers, with inventory and overseas warehouse capability. Important controls are incomplete: there is no valid manufacturing-capacity contract with related subcontractors, no continuous batch quantity reconciliation, and no outsourcing SOP.

Customization capabilityThe supplier explicitly offers customization from samples, customization from designs, full customization, minor customization, and flexible customization, supported by stated R&D and ODM capabilities. This is direct evidence of broad customization coverage.